The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Evaluating the side effects of 2L treatment for upper gastrointestinal cancer
Timothy Brown, MD, UT Southwestern Medical Center, Dallas, TX, highlights the importance of dialogue between patients and clinicians regarding the side effects and treatment logistics when choosing a second-line treatment for upper gastrointestinal cancer. While ramucirumab with FOLFIRI or paclitaxel are second-line options for patients with minimal neuropathy from first-line treatment, Dr Brown encourages these patients with to opt for FOLFIRI with ramucirumab, which has fewer side effects without reducing second-line survival benefit. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
